Claudio Guerreiro

Dr. Claudio Guerreiro

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2017 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
JAJoão G. Almeida
João G. Almeida
SFSara M. Ferreira
Sara M. Ferreira
PFPaulo Fonseca
Paulo Fonseca
TDTiago Dias
Tiago Dias
CGClaudio Guerreiro
Claudio Guerreiro
VRVasco G. Ribeiro
Vasco G. Ribeiro

14 August 2023 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
Miguel Nobre MenezesMiguel Nobre Menezes
Miguel Nobre Menezes
BSBeatriz Silva
Beatriz Silva
JSJoão Lourenço Silva
João Lourenço Silva
TRTiago Rodrigues
Tiago Rodrigues
JMJoão Silva Marques
João Silva Marques
FPFausto J. Pinto
Fausto J. Pinto

1 June 2020 in Journal of Cardiovascular Medicine
Verified
Journal Article
Closed access
CGClaudio Guerreiro
Claudio Guerreiro
PAPedro Azevedo
Pedro Azevedo
RLRicardo Ladeiras-Lopes
Ricardo Ladeiras-Lopes
NFNuno Ferreira
Nuno Ferreira
ABAna Raquel Barbosa
Ana Raquel Barbosa
PBPedro Braga
Pedro Braga
Aims The diagnostic performance of the new Peguero–Lo Presti ECG criteria for left ventricular hypertrophy (LVH) has not been validated by cardiac magnetic resonance (CMR). The aim of this study was to evaluate and compare the diagnostic performance of Peguero–Lo Presti, Cornell and Sokolow--Lyon voltage criteria for LVH as defined by CMR in an all-comers European population. Methods A total of 240 consecutive patients referred for CMR who had a concomitant electrocardiogram for review were evaluated. LVH group patients were defined according to the reference values for sex and age of left ventricular mass index (LVMi). A control group, adjusted by sex, was randomly selected from a population without LVH. We applied the ECG voltage criteria to both groups and evaluated their diagnostic accuracy. Diagnostic sensitivity and specificity were compared. Results Two hundred and forty patients (mean age 63 years; 65% men) were divided into two groups (LVH n = 149; control n = 91). The main causes of LVH were hypertension (24.8%) and hypertrophic cardiomyopathy (21.5%). The remaining patients of this group had a diagnosis of dilated cardiomyopathy (14.8%), valvular heart disease (7.4%) and infiltrative cardiomyopathy (2.0%). Overall, the sensitivity for LVH diagnosis of the Peguero–Lo Presti criteria outperformed both the Cornell (47 vs. 29%, P < 0.001) and Sokolow--Lyon voltage criteria (vs. 25%, P < 0.001). The specificities of all the criteria were above 94%, without significant differences between them. Conclusion In an all-comers European population with LVH defined by CMR, the criteria of Peguero–Lo Presti showed increased sensitivity for this diagnosis, when compared with the Sokolow--Lyon and Cornell voltage criteria. As such, they could become the preferred ECG diagnostic tool when evaluating patients at risk for LVH.

26 April 2016 in Echocardiography
Verified
Journal Article
Closed access
PDF file
CGClaudio Guerreiro
Claudio Guerreiro
CFConceição Fonseca
Conceição Fonseca
JRJosé Ribeiro
José Ribeiro
RFRicardo Fontes‐Carvalho
Ricardo Fontes‐Carvalho

5 January 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
FDFabiana Duarte
Fabiana Duarte
IAInês Aguiar‐Neves
Inês Aguiar‐Neves
CGClaudio Guerreiro
Claudio Guerreiro
MSMariana Silva
Mariana Silva
NFNuno D. Ferreira
Nuno D. Ferreira
RFRicardo Fontes‐Carvalho
Ricardo Fontes‐Carvalho

30 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AMAlfonso Reyes Mitre
Alfonso Reyes Mitre
HGHector Lopez de la Garza
Hector Lopez de la Garza
CGClaudio Guerreiro
Claudio Guerreiro
DODahyr Olivas-Medina
Dahyr Olivas-Medina
EGErick Marlon Avila Gil
Erick Marlon Avila Gil
VDVictor Alfonso Jiménez Diaz
Victor Alfonso Jiménez Diaz
Transcatheter aortic valve replacement (TAVR) has evolved over the last two decades into a cornerstone therapy for patients with severe symptomatic aortic stenosis. This therapy was initially reserved for those at high or prohibitive surgical risk but is now firmly established across all surgical risk categories. Its non-inferiority to surgical aortic valve replacement has been demonstrated even in low-risk populations, supporting the rapid worldwide expansion of its use. Nevertheless, despite procedural refinements and the advent of newer-generation prostheses, conduction disturbances leading to permanent pacemaker implantation (PPI) remain one of the most frequent and clinically relevant complications. Reported incidence ranges between 8% and 20% depending on prosthesis type, implantation technique, and baseline patient characteristics. Multiple clinical, anatomical, and procedural factors have been identified as strong predictors of post-TAVR conduction disturbances. Taken together, the integration of anatomical and clinical risk assessment, precise procedural planning, careful device selection, structured monitoring, and emerging therapeutic strategies constitutes a comprehensive, evidence-based approach to reduce the burden of conduction disturbances following TAVR. Such a multimodal framework has the potential not only to lower the incidence of permanent pacemaker implantation but also to improve safety, optimize healthcare resource utilization, and support the broader adoption of TAVR in increasingly younger and lower-risk patient populations.